Tag: longacting
Teva and Medincell Announce Positive Efficacy Results for Phase 3 SOLARIS Trial of TEV-‘749 (olanzapine/mdc-TJK), Monthly Long-Acting Subcutaneous Injection for Adults With Schizophrenia – 08/05/ 2024 at 12:30
The study met its primary endpoint in all groups receiving doses of TV-‘749 compared to the placebo group, achieving clinically remarkable and statistically significant reductions in total score on the…
MedinCell – Partner Teva provides 2024 sales forecast for UZEDY™ and provides update on long-acting injectable olanzapine treatment candidate – 01/31/2024 at 10:00 p.m.
· UZEDY revenue forecast for Teva in 2024: ~$80 million · Ongoing phase 3 of Olanzapine LAI: l675 patients (recruitment completed), 62% of 3,600 planned injections completed, no PDSS (post-injection…
MedinCell – Partner Teva announces the end of patient recruitment in the phase 3 clinical study of mdc-TJK, long-acting injectable treatment of olanzapine – 01/09/2024 at 7:20 p.m.
Teva Pharmaceuticals Industries Ltd., announced at the JP Morgan Healthcare Conference that it has successfully completed recruitment in Europe and the United States of the planned 640 participants in the…
MedinCell: start of the Phase 3 study for the second long-acting injectable antipsychotic
Through Olivier Cheilan Published on 01/24/2023 at 6:20 p.m. (Boursier.com) —…
Launch of a phase 3 study for the second long-acting injectable antipsychotic using MedinCell technology – 08/29/2022 at 18:00
Teva Pharmaceuticals has informed MedinCell of its decision to initiate the Phase 3 clinical trial for mdc-TJK. MedinCell will immediately receive a $3 million payment from Teva Pharmaceuticals for reaching…